根据Exact Sciences的建模数据预测，在过去10年中，已有超过1600万人通过Cologuard测试完成了筛查。这也推动了美国50-75岁群体的结肠癌筛查率，从2015年的63%上升到2021年的72%。 这一极具社会价值的成就，为Exact ...

MADISON, Wis., September 16, 2024--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced performance data for its blood-based colorectal ...

In July, the Summer Law and Trial Institute (SLTI) welcomed 24 high school students from across the state of Ohio both to Athens and to the practice of law. OHIO's faculty and staff, across various ...

Exact Sciences Corp (EXAS) stock saw a modest uptick, ending the day at $69.21 which represents a slight increase of $1.22 or 1.79% from the prior close of $67.99. The stock opened at $68.14 and ...

Health officials on Thursday said they don’t know how a Missouri person caught bird flu but believe it may be a rare instance of a “one-off” standalone ...

A rival CEO's confrontational social media post underscored the high stakes in the race to develop and deploy cancer ...

Positive results of a colon cancer study conducted by Exact Sciences prompt the CEO of competitor Guardant Health to publicly ...

周一，Canaccord Genuity重申了Exact Sciences Corporation (NASDAQ:EXAS)的买入评级，并维持75美元的目标价。这一背书是在该公司在2024年欧洲医学肿瘤学会（ESMO）大会上宣布其基于血液的结直肠癌（CRC）筛查测试的新性能数据之后做出的。 这项旨在提高新型生物标志物特异性的测试显示，对CRC的检测敏感性为88%，对进展性腺瘤（AA）的敏感性为3 ...

Analyst Tycho Peterson of Jefferies assigned a Buy rating on Exact Sciences (EXAS – Research Report), with a price target of $84.00.

Analyst Brandon Couillard of Wells Fargo maintained a Buy rating on Exact Sciences (EXAS – Research Report), retaining the price target ...

周一,BTIG更新了对Exact Sciences Corp (NASDAQ:EXAS)的展望,将目标价从之前的70美元上调至82美元,同时重申对该股的买入评级。此次调整是在市场对Exact Sciences最近在European Society of Medical Oncology (ESMO)会议上展示的基于血液的结直肠癌 (CRC)检测数据反应积极之后做出的。